Balyasny Asset Management
BSTC

Balyasny Asset Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Balyasny Asset Management’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,604
Closed -$204K – 2307
2018
Q1 		$204K Buy
+4,604
New +$193K ﹤0.01% 1760
2017
Q4 		– Sell
-5,204
Closed -$242K – 2437
2017
Q3 		$242K Buy
+5,204
New +$249K ﹤0.01% 1621

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's BSTC Position: Q2 2018 in Review

Balyasny Asset Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q2 2018, closing a stake of 4,604 shares — an estimated $204K sold.

Balyasny Asset Management first reported a position in BSTC in Q3 2017 and held it in 2 quarters. The position peaked at $242K in Q3 2017. 80 funds tracked by Wall St. Rank hold BSTC as of Q2 2018.

  • Balyasny Asset Management reported no remaining BioSpecifics Technologies Corp. position as of Q2 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 4,604 BioSpecifics Technologies Corp. shares in Q2 2018, an estimated $204K.
  • Balyasny Asset Management first reported a position in BioSpecifics Technologies Corp. in Q3 2017 and held it in 2 quarters.
  • Balyasny Asset Management's BioSpecifics Technologies Corp. position peaked at $242K in Q3 2017.
  • 80 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.